drugset / Trial / NCT01416883

Oral Mucosal Absorption Study of Bicalutamide New Formulation

NCT01416883

Phase 1 Terminated 8 enrolled AstraZeneca
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to investigate the presence or absence of oral mucosal absorption of bicalutamide after ICI176,334.1 is given to Japanese healthy male subjects

Timeline

Start
2010-07
Primary completion
2010-08
Completion
2010-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Bicalutamide Other / unclassified

Indications

No indication recorded.